ARA-290 (Cibinetide) is a synthetic 11-amino acid peptide derived from erythropoietin designed to support tissue repair and reduce chronic neuropathic pain. It functions by selectively targeting the innate repair receptor (IRR) without stimulating red blood cell production. [1, 2, 3]
Key Details & Clinical Research
- Primary Use: Studied primarily for managing chronic pain, small-fiber neuropathy, and diabetes-related nerve damage by reducing local inflammation and repairing small nerve fibers. [1, 2]
- Regulatory Status: Not approved by the FDA for human medical use. Development stalled following the closure of its developer, Araim Pharmaceuticals. [1]
- Clinical Findings: In Phase II clinical trials, the compound was evaluated for its ability to reduce neuropathic pain and address nerve damage, with studies often utilizing subcutaneous administration. [1, 2]
- Mechanism: Binds to the IRR to trigger anti-inflammatory and cytoprotective (cell-protecting) actions in damaged tissues. [1, 2]




Reviews
There are no reviews yet.